Supporting information

Redox-Responsive Heparin–Chlorambucil Conjugate Polymeric Prodrug for Improved Anti-Tumor Activity

Abegaz Tizazu Andrgie 1, Yihenew Simegniew Birhan 1, Tefera Worku Mekonnen 1, Endiries Yibru Hanurry 1, Haile Fentahun Darge 1, Rong-Ho Lee 2, Hsiao-Ying Chou 1 and Hsieh-Chih Tsai 1,3,*

1 Graduate Institute of Applied Science and Technology, National Taiwan University of Science and Technology, Taipei 106, Taiwan, ROC; habegaz21@gmail.com (A.T.A.); yihenews@gmail.com (Y.S.B.); tefe16@gmail.com (T.W.M.); Endris_Yibru@dmu.edu.et (E.Y.H.); fentahunhailebdu@gmail.com (H.F.D.); wherelove8@gmail.com (H.Y.C.)

2 Department of Chemical Engineering, National Chung Hsing University, Taichung 402, Taiwan; rhl@dragon.nchu.edu.tw

3 Advanced Membrane Materials Center, National Taiwan University of Science and Technology, Taipei 106, Taiwan

* Correspondence: h.c.tsai@mail.ntust.edu.tw; Tel.: +886-2-27303625; Fax: +886-2-27303733

Figure S1. FTIR spectrum of heparin (black), PNIPAm-NH₂ (red), and conjugation (copolymer) (blue).

Polymers 2020, 12, x; doi: FOR PEER REVIEW www.mdpi.com/journal/polymers
Figure S2. Particle morphology by AFM imaging of Hep-Chl-1 prodrug nanoparticles and after treatment either with 6 mM GSH and 0.1% H₂O₂.
Figure S3. The size of Hep-Chl-1 prodrug nanoparticles after incubating in human serum albumin and PBS with 1, 2, 4, 8, 16, 24, 48, and 72 h at 37 °C.

Figure S4. MTT profiles of (a) HeLa cells and (b) RAW264.7 cells treated with Chl and Hep-Chl (equivalent amount of Chl) for 24 and 72 h.
**Figure S5.** The fluorescence intensity measuring Rhodamine B labeled Hep-Chl-1 prodrug nanoparticle.